IR exec leaves Bayer for Celyad

Carri Duncan has left her role as senior investor relations manager with German pharma major Bayer (BAYN: DE) to join the CAR-T specialist Celyad (Nasdaq: CYAD).

Dr Duncan, whose prior experience also includes working as an equities analyst with Credit Suisse (CSGN: VTX) and more than a decade as a molecular and cell biologist in academia and with Novartis (NOV: VX) and Eli Lilly (NYSE: LLY), joins the Belgian biotech as vice president, corporate development and communications.

In a press release, the company called it “yet another strategic hire to prepare Celyad for its next level of success.”